Special Issue "Cancer Diagnosis and Targeted Therapy"

Quicklinks

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (31 January 2011)

Special Issue Editor

Guest Editor
Dr. Veronique Baud
1 Institut Cochin, Centre national de la recherche scientifique (CNRS) UMR 8104, Inserm U1016, Paris, France
2 Immunology-Hematology Department, Université Paris Descartes, 123 Boulevard de Port-Royal, 75014 Paris, France
Website: http://cochin.inserm.fr/research/scientific-departments/ih/team
E-Mail: veronique.baud@inserm.fr
Interests: interface between signal transduction and cancer with a focus on the alternative NF-kappaB signaling pathway, how it is regulated, and its contributions towards tumor development and resistance to conventional cancer therapies

Special Issue Information

Dear Colleagues,

Although mortality rates have declined in recent years, the majority of cancers are still difficult to treat and the medical need for better cancer treatment is evident. The current anticancer armamentarium includes many active agents that are applied across tumor types, and most drugs have a small therapeutic index and barely discriminate between malignant and normal cells. In recent years the focus has shifted to the development of rationally designed, molecularly-targeted therapy for the treatment of a specific cancer, therefore offering the promise of greater specificity coupled with reduced systemic toxicity. Another challenge has been the development of prognostic and pharmacogenomic biomarkers that enable the targeting of individualized treatments to those patients most likely to benefit.

This special issue will explore the routes from cancer research and oncogenomics into the development of novel mechanism-based cancer therapeutics and biomarkers.

We invite research and review papers in any area of oncology that are related, but not limited to, fundamental understanding of oncogenomics and cancer signaling pathways, diagnostic, prognostic and pharmacogenomic biomarkers, molecular diagnosis by gene expression profiling, molecular targets driving the progression of human cancers, cancer drug development on these targets, clinical trial with new agents, validation in animal models.

Dr. Veronique Baud
Guest Editor

Keywords

  • cancer targeted diagnosis
  • cancer targeted therapeutics
  • solid tumors
  • hematological malignancies
  • oncogenomics
  • gene expression profiling
  • molecular targets
  • mechanism-based drug development
  • biomarkers
  • miRNA
  • ubiquitin-proteasome pathway
  • clinical trials
  • animal models

Published Papers (20 papers)

Cancers 2012, 4(2), 523-530; doi:10.3390/cancers4020523
Received: 8 March 2012; in revised form: 31 March 2012 / Accepted: 23 April 2012 / Published: 8 May 2012
Show/Hide Abstract | Download PDF Full-text (263 KB) | Download XML Full-text

Cancers 2011, 3(4), 4170-4190; doi:10.3390/cancers3044170
Received: 18 July 2011; in revised form: 14 November 2011 / Accepted: 16 November 2011 / Published: 23 November 2011
Show/Hide Abstract | Download PDF Full-text (542 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(4), 3838-3855; doi:10.3390/cancers3043838
Received: 22 August 2011; in revised form: 27 September 2011 / Accepted: 27 September 2011 / Published: 11 October 2011
Show/Hide Abstract | Download PDF Full-text (289 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(3), 3506-3524; doi:10.3390/cancers3033506
Received: 9 August 2011; in revised form: 30 August 2011 / Accepted: 5 September 2011 / Published: 13 September 2011
Show/Hide Abstract | Download PDF Full-text (251 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2734-2749; doi:10.3390/cancers3022734
Received: 12 May 2011; in revised form: 16 June 2011 / Accepted: 17 June 2011 / Published: 21 June 2011
Show/Hide Abstract | Download PDF Full-text (482 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(2), 2597-2629; doi:10.3390/cancers3022597
Received: 11 March 2011; in revised form: 2 May 2011 / Accepted: 31 May 2011 / Published: 9 June 2011
Show/Hide Abstract | Download PDF Full-text (488 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2402-2420; doi:10.3390/cancers3022402
Received: 30 January 2011; in revised form: 29 April 2011 / Accepted: 5 May 2011 / Published: 16 May 2011
Show/Hide Abstract | Download PDF Full-text (340 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2316-2332; doi:10.3390/cancers3022316
Received: 30 January 2011; in revised form: 15 April 2011 / Accepted: 28 April 2011 / Published: 11 May 2011
Show/Hide Abstract | Download PDF Full-text (236 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2255-2273; doi:10.3390/cancers3022255
Received: 11 March 2011; in revised form: 11 April 2011 / Accepted: 26 April 2011 / Published: 3 May 2011
Show/Hide Abstract | Download PDF Full-text (260 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2243-2254; doi:10.3390/cancers3022243
Received: 4 March 2011; in revised form: 10 April 2011 / Accepted: 13 April 2011 / Published: 3 May 2011
Show/Hide Abstract | Download PDF Full-text (229 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2214-2222; doi:10.3390/cancers3022214
Received: 6 February 2011; in revised form: 4 April 2011 / Accepted: 14 April 2011 / Published: 28 April 2011
Show/Hide Abstract | Download PDF Full-text (633 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(2), 2131-2140; doi:10.3390/cancers3022131
Received: 18 February 2011; in revised form: 8 April 2011 / Accepted: 12 April 2011 / Published: 26 April 2011
Show/Hide Abstract | Download PDF Full-text (166 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 2014-2031; doi:10.3390/cancers3022014
Received: 4 February 2011; in revised form: 19 March 2011 / Accepted: 24 March 2011 / Published: 18 April 2011
Show/Hide Abstract | Download PDF Full-text (615 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 1899-1928; doi:10.3390/cancers3021899
Received: 23 February 2011; in revised form: 23 March 2011 / Accepted: 1 April 2011 / Published: 8 April 2011
Show/Hide Abstract | Download PDF Full-text (444 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(2), 1877-1898; doi:10.3390/cancers3021877
Received: 27 January 2011; in revised form: 25 March 2011 / Accepted: 1 April 2011 / Published: 8 April 2011
Show/Hide Abstract | Download PDF Full-text (581 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(1), 1372-1382; doi:10.3390/cancers3011372
Received: 6 February 2011; in revised form: 9 March 2011 / Accepted: 11 March 2011 / Published: 16 March 2011
Show/Hide Abstract | Download PDF Full-text (511 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Cancers 2011, 3(1), 1129-1140; doi:10.3390/cancers3011129
Received: 4 January 2011; in revised form: 28 February 2011 / Accepted: 1 March 2011 / Published: 7 March 2011
Show/Hide Abstract | Download PDF Full-text (161 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(1), 913-926; doi:10.3390/cancers3010913
Received: 17 January 2011; in revised form: 9 February 2011 / Accepted: 22 February 2011 / Published: 28 February 2011
Show/Hide Abstract | Download PDF Full-text (197 KB) | View HTML Full-text | Download XML Full-text

Cancers 2011, 3(1), 773-788; doi:10.3390/cancers3010773
Received: 24 January 2011; in revised form: 5 February 2011 / Accepted: 21 February 2011 / Published: 23 February 2011
Show/Hide Abstract | Download PDF Full-text (164 KB) | View HTML Full-text | Download XML Full-text

Cancers 2010, 2(4), 1838-1860; doi:10.3390/cancers2041838
Received: 15 October 2010; in revised form: 3 November 2010 / Accepted: 4 November 2010 / Published: 5 November 2010
Show/Hide Abstract | Download PDF Full-text (530 KB) | Download XML Full-text

Last update: 25 February 2014

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert